<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Spectranetics Corporation</title>
	<atom:link href="http://www.stockbloghub.com/tag/spectranetics-corporation/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(KNSY) Kensey Beats Consensus Estimate</title>
		<link>http://www.stockbloghub.com/2009/08/24/knsy-kensey-beats-consensus-estimate/13227</link>
		<comments>http://www.stockbloghub.com/2009/08/24/knsy-kensey-beats-consensus-estimate/13227#comments</comments>
		<pubDate>Mon, 24 Aug 2009 20:39:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[Kensey Nash Corporation]]></category>
		<category><![CDATA[KNSY]]></category>
		<category><![CDATA[Orthovita Incorporated]]></category>
		<category><![CDATA[Spectranetics Corporation]]></category>
		<category><![CDATA[SPNC]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[VITA]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13227</guid>
		<description><![CDATA[Kensey Nash Corp. (KNSY) recently reported strong results for the fourth quarter and full year 2009. Quarterly profit came in at 41 cents per share, compared to the Zacks Consensus Estimate of 38 cents and the year-ago loss of 9 cents per share. Quarterly Results Sales Net sales in the quarter were $20.5 million, down about 7% year over year. In terms of business segments, sales of Biomaterials products fell 8% year over year to $12.3 million. Within this segment, Orthopaedic revenue declined 16% year over year to $7 million on lower sales of sports medicines due to the ongoing economic turbulence. This was partly offset by higher sales of the Vitoss Bioactive Foam products to its customer Orthovita Inc. (VITA). Cardiovascular sales rose 8% year over year to $4.5 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/24/knsy-kensey-beats-consensus-estimate/13227/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CSII) Cardiovascular Systems Better Than Expected Results</title>
		<link>http://www.stockbloghub.com/2009/08/20/cardiovascular-systems-better-than-expected-results/12916</link>
		<comments>http://www.stockbloghub.com/2009/08/20/cardiovascular-systems-better-than-expected-results/12916#comments</comments>
		<pubDate>Thu, 20 Aug 2009 18:51:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Cardiovascular Systems Incorporated]]></category>
		<category><![CDATA[CSII]]></category>
		<category><![CDATA[Ev3 Incorporated]]></category>
		<category><![CDATA[EVVV]]></category>
		<category><![CDATA[Spectranetics Corporation]]></category>
		<category><![CDATA[SPNC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=12916</guid>
		<description><![CDATA[Cardiovascular Systems, Inc. (CSII) reported better-than-expected results for the fourth quarter of fiscal 2009. For the quarter, its loss per share was 40 cents, better than the Zacks Consensus Estimate of 58 cents and the year-ago loss per share of $2.34. Quarterly results Sales Net sales in the quarter increased roughly 59% year over year to $15.7 million. Growth was primarily due to increased adoption of company product the Diamondback 3600.  The number of hospitals using the Diamondback 3600 was 556, compared to 183 at the end of the year-ago quarter. Higher sales of disposable devices also contributed to the total growth in net sales. The number of disposable devices sold in the quarter was 4,700 units, compared to 3,000 units in the year-ago quarter. Margins Gross margin increased 1,020 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/20/cardiovascular-systems-better-than-expected-results/12916/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

